Synchrony Financial Announces Quarterly Common Stock Dividend of $0.15 Per Share

STAMFORD, Conn.--(BUSINESS WIRE)-- Synchrony Financial (NYSE: SYF) announced today that its Board of Directors declared a quarterly cash dividend of $0.15 per share of common stock, payable on November 16, 2017 to holders of record at the close of business on November 6, 2017.

About Synchrony Financial

Synchrony Financial (NYSE: SYF) is one of the nation’s premier consumer financial services companies. Our roots in consumer finance trace back to 1932, and today we are the largest provider of private label credit cards in the United States based on purchase volume and receivables.* We provide a range of credit products through programs we have established with a diverse group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations and healthcare service providers to help generate growth for our partners and offer financial flexibility to our customers. Through our partners’ over 365,000 locations across the United States and Canada, and their websites and mobile applications, we offer our customers a variety of credit products to finance the purchase of goods and services. Synchrony Financial offers private label credit cards, Dual Card™ and general purpose co-branded credit cards, promotional financing and installment lending, loyalty programs and FDIC-insured savings products through Synchrony Bank. More information can be found at www.synchronyfinancial.com, facebook.com/SynchronyFinancial, www.linkedin.com/company/synchrony-financial and twitter.com/SYFNews.

*Source: The Nilson Report (June 2017, Issue # 1112) - based on 2016 data.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171025005094/en/

Synchrony Financial
Investor Relations:
Greg Ketron, 203-585-6291
or
Jennifer Church, 203-585-6508
[email protected]
or
Media Relations:
Lisa Lanspery, 203-585-6143
or
Dori Abel, 203-585-6702
[email protected]

Source: Synchrony Financial

You May Also Be Interested In

• Belden completes acquisition of Ruckus Networks from Vistance
• InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
• Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formu